CVS Health Puts A Price On GLP-1 Value: About $350 A Month

3 days ago 4

A new CVS Health analysis of Aetna claims data finds that GLP-1 medicines deliver better outcomes, fewer hospital visits and lower medical spending — but at current prices those savings do not yet offset what health plans spend on the drugs themselves, with break-even modeled at a net price of roughly $350 per month.

The Question Employers Are Actually Asking

CVS Health framed its new research around the question now sitting on every employer’s benefits desk: as GLP-1 use grows, do the medicines save enough elsewhere in the health care system to offset their cost? “The answer, at current prices, is not yet,” the company said in releasing the study on Nov. 15. The white paper is titled “GLP-1s: Good Drugs, High Prices.”

The analysis used anonymized Aetna claims data from commercial fully insured members. Researchers examined members who used GLP-1s, with index years from 2023 through 2025 and up to three years of follow-up, and matched them with similar non-users based on age, existing health conditions, prior health care use and prior medical and pharmacy spending. That matched design matters: it is the company’s attempt to compare people who started the medicines with people like them who did not, rather than simply describing everyone who filled a prescription.

“GLP-1s are remarkably effective medicines, and the health benefits are real. The challenge is making those benefits affordable at scale,” said Dr. Amy Compton-Phillips. “That means getting treatment to the people most likely to benefit, helping them stay on therapy and bringing the price to a level that supports broader access.”

What The Independent Numbers Add

Reuters’ report on the study, published Nov. 14, adds the specific figures behind the headline. CVS said GLP-1 use for obesity, diabetes or other conditions was associated with 10 to 12 percent lower emergency room visits in the first and second year of use, examining records for 60,000 people during the first year and 20,000 people for a second year. Among 4,000 people still taking the drug after three years, hospitalizations decreased by 34 to 42 percent, according to the report.

The money, however, does not yet balance. Across those three years, Reuters reported, plan sponsors saved $9,400 per person on medical bills but spent $13,300 more on prescriptions — a net added cost of $3,900 per person. The analysis did not break out figures for obesity patients alone. CVS’s own modeling lands on the same conclusion from the other direction: across the study population, a net price of approximately $350 per month over three years would bring pharmacy spending and observed medical savings into balance. The company is careful to note that the break-even point varies with a patient’s underlying clinical risk, how long they remain on treatment and how consistently they take the medication. Compton-Phillips made the same point in clinical terms to Reuters: “An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes. The higher-risk the person is, the quicker you get to a return on investment.”

Adherence Is Part Of The Economics

CVS also tested whether staying on treatment changes the value equation. Researchers compared everyone who started a GLP-1 with the subgroup whose prescriptions covered at least 80 percent of days during follow-up, a standard measure of medication adherence. The company’s three conditions for getting more value from the drugs follow directly from that work: treat the right patients, prioritizing people most likely to benefit based on clinical evidence and individual need; help people stay on therapy long enough to realize the health benefits; and lower the price so improved outcomes translate into sustainable access and overall costs.

That middle condition is easy to overlook and expensive to ignore. A medicine that reduces hospitalizations over two and three years cannot produce those savings for a patient who stops filling it in month four — but the plan has still paid for the months of therapy. In CVS’s framing, adherence support is not a wellness extra; it is part of what determines whether the drug spend ever pays for itself.

The Price Gap, In Market Terms

Reuters placed the $350 figure against what buyers actually pay. Cash-pay customers can pay about $299 for Zepbound and $349 for Wegovy, while employers and other health plan sponsors pay between $617 and $766 per month for the drugs, according to a 2025 study by the Employee Benefit Research Institute cited in the report. CVS declined to comment on the average prices it pays. Compton-Phillips argued that the drugmakers’ direct-to-consumer prices suggest they can still profit by charging less than $350 a month while helping lower overall health care costs. “I hope that we can reach that price sooner rather than later,” she said ahead of the HLTH conference in Las Vegas, where CVS presented the findings on Nov. 15.

The pressure is already changing coverage. Reuters reported that coverage of GLP-1 drugs for obesity is falling as corporations and other plan sponsors try to contain premiums expected to rise by over 9 percent in 2027, and that about 14 percent of companies have already dropped or plan to drop the drugs in 2027. For context on what a negotiated public price can look like, the report noted that the U.S. government agreed a deal with Eli Lilly and Novo Nordisk last year to pay $245 per month for injectable GLP-1 weight-loss drugs in an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or with disabilities. The drugs in the CVS analysis were the Lilly and Novo Nordisk medicines that mimic the GLP-1 hormone and reduce appetite, including Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity.

Why The Stakes Keep Growing

The affordability fight is intensifying because the eligible population keeps expanding. Originally developed for type 2 diabetes, GLP-1 medicines now have approved uses across obesity and cardiovascular, liver and kidney disease, CVS noted, and its white paper counts more than 137 million U.S. adults as medically eligible for semaglutide across indications, many qualifying under more than one. CVS is explicit that financial break-even should not be the sole measure of a medicine’s value. Its argument is narrower and, for the employers and health plans deciding coverage this cycle, more pointed: the health benefits are documented in its data, the medical savings are real but smaller than the pharmacy bill at today’s prices, and the distance between the two is, to a first approximation, about $350 a month.

Source: CVS Health via PR Newswire, “GLP-1s: Good Drugs, High Prices” white paper announcement; Reuters reporting on the study via Q106.

The post CVS Health Puts A Price On GLP-1 Value: About $350 A Month appeared first on The Hype Magazine.

Read Entire Article